Tenon Medical, Inc. (NASDAQ: TNON) recently announced successful outcomes in the initial phase of its clinical study for the Catamaran SE SI Joint Fixation Device, spurring a notable increase in its stock value. As of the latest pre-market data, TNON shares are trading at $3.92, marking a 20.24% rise, driven by growing optimism about the potential of this innovative implant.
Enhancements in Device Design and Application
The Catamaran SE, a new iteration of Tenon’s established SI Joint Fixation Device, boasts a 30% reduction in implant width, enabling its application in patients with smaller sacroiliac (SI) joint anatomy and in cases where revision of failed SI joint implants is required.
This size reduction offers significant advantages for surgeons, particularly in anatomies with limited space or in previously treated joints that demand more precision. The initial feedback from physicians using the Catamaran SE is expected to aid Tenon in refining the product for a broader market release in the coming months.
Expanding Clinical Reach Across Centers of Excellence
Clinical procedures with the Catamaran SE have been successfully performed at multiple medical centers of excellence, including locations in Idaho, Pennsylvania, Minnesota, Arizona, and Utah. This successful deployment underscores the device’s potential in achieving stable fixation of the SI joint through a minimally invasive approach.
The Catamaran and Catamaran SE devices consist of MRI-compatible titanium implants with a two-pontoon system connected by an osteotome bridge, which allows for secure, longitudinal fixation of the joint.
Commitment to AO Principles and Broader Patient Options
Tenon Medical designed the Catamaran SE in line with the AO principles of arthrodesis, which emphasize joint preparation, rigid fixation, and adequate bone grafting. Both devices are implanted using a minimally invasive approach targeting the sacrum and ilium’s dense cortical bone, aiming to achieve long-term fusion of the SI joint. To date, over 750 Catamaran devices have been successfully implanted, addressing primary SI joint dysfunction and revision cases.
Strategic Market Expansion for SI Joint Fixation
Following the promising outcomes from the Catamaran SI Joint Fusion System MAINSAIL Study, Tenon Medical (TNON) is now positioned to offer physicians a versatile portfolio of SI joint fixation solutions. This expanded offering aims to address the diverse anatomical needs of patients and refine treatment strategies, ultimately broadening TNON’s market reach and enhancing options for patients and healthcare providers alike.